Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies

Nature Medicine

Volumn 19, Issue 8, 2013, Pages 998-1004

  Lee, Andrew S ^a   Tang, Chad ^a,b   Rao, Mahendra S ^c   Weissman, Irving L ^a   Wu, Joseph C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGENICITY; CELL POPULATION; CELL PROLIFERATION; CONTACT INHIBITION; DNA REPAIR; EMBRYONIC STEM CELL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE EXPRESSION; GERM LAYER; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; LIVER CELL CARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MALIGNANT TRANSFORMATION; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; TERATOMA;

CELL TRANSFORMATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; NEOPLASMS; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELLS; STEM CELL TRANSPLANTATION;

EID: 84882239370     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3267     Document Type: Review

References (70)

1. Ben-David, U. & Benvenisty, N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat. Rev. Cancer 11, 268-277 (2011).
2. DeFrancesco, L. Fits and starts for Geron. Nat. Biotechnol. 27, 877 (2009).
3. Lee, A.S. et al. Effects of cell number on teratoma formation by human embryonic stem cells. Cell Cycle 8, 2608-2612 (2009).
4. Roy, N.S. et al. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat. Med. 12, 1259-1268 (2006).
5. Kriks, S. et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 480, 547-551 (2011).
6. Cui, L. et al. WNT signaling determines tumorigenicity and function of ESC-derived retinal progenitors. J. Clin. Invest. 123, 1647-1661 (2013).
7. Doi, D. et al. Prolonged maturation culture favors a reduction in the tumorigenicity and the dopaminergic function of human ESC-derived neural cells in a primate model of Parkinson's disease. Stem Cells 30, 935-945 (2012).
8. Amariglio, N. et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med. 6, e1000029 (2009).
9. Cyranoski, D. Strange lesions after stem-cell therapy. Nature 465, 997 (2010).
10. Strauss, S. Geron trial resumes, but standards for stem cell trials remain elusive. Nat. Biotechnol. 28, 989-990 (2010).
11. Schwartz, S.D. et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 379, 713-720 (2012).
12. Cyranoski, D. Stem cells cruise to clinic. Nature 494, 413 (2013).
13. Ben-Porath, I. et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40, 499-507 (2008).
14. Kim, J. et al. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 143, 313-324 (2010).
15. Närvä, E. et al. High-resolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity. Nat. Biotechnol. 28, 371-377 (2010).
16. Meyer, N. & Penn, L.Z. Reflecting on 25 years with MYC. Nat. Rev. Cancer 8, 976-990 (2008).
17. Okita, K., Ichisaka, T. & Yamanaka, S. Generation of germline-competent induced pluripotent stem cells. Nature 448, 313-317 (2007).
18. Markoulaki, S. et al. Transgenic mice with defined combinations of drug-inducible reprogramming factors. Nat. Biotechnol. 27, 169-171 (2009).
19. Wernig, M., Meissner, A., Cassady, J.P. & Jaenisch, R. c-Myc is dispensable for direct reprogramming of mouse fibroblasts. Cell Stem Cell 2, 10-12 (2008).
20. Lin, C.Y. et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151, 56-67 (2012).
21. Hochedlinger, K., Yamada, Y., Beard, C. & Jaenisch, R. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 121, 465-477 (2005).
22. Lee, T.K., Cheung, V.C. & Ng, I.O. Liver tumor-initiating cells as a therapeutic target for hepatocellular carcinoma. Cancer Lett. published online http://dx.doi.org/10.1016/j.canlet.2012.05.001 (28 May 2012).
23. Bass, A.J. et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat. Genet. 41, 1238-1242 (2009).
24. Rowland, B.D., Bernards, R. & Peeper, D.S. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat. Cell Biol. 7, 1074-1082 (2005).
25. Mikkelsen, T.S. et al. Dissecting direct reprogramming through integrative genomic analysis. Nature 454, 49-55 (2008).
26. Soldner, F. et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136, 964-977 (2009).
27. Woltjen, K. et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 458, 766-770 (2009).
28. Stadtfeld, M., Nagaya, M., Utikal, J., Weir, G. & Hochedlinger, K. Induced pluripotent stem cells generated without viral integration. Science 322, 945-949 (2008).
29. Yu, J. et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 324, 797-801 (2009).
30. Jia, F. et al. A nonviral minicircle vector for deriving human iPS cells. Nat. Methods 7, 197-199 (2010).
31. Ban, H. et al. Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc. Natl. Acad. Sci. USA 108, 14234-14239 (2011).
32. Warren, L. et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7, 618-630 (2010).
33. Lee, J. et al. Activation of innate immunity is required for efficient nuclear reprogramming. Cell 151, 547-558 (2012).
34. Miyoshi, N. et al. Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell 8, 633-638 (2011).
35. Nakagawa, M., Takizawa, N., Narita, M., Ichisaka, T. & Yamanaka, S. Promotion of direct reprogramming by transformation-deficient Myc. Proc. Natl. Acad. Sci. USA 107, 14152-14157 (2010).
36. Desponts, C. & Ding, S. Using small molecules to improve generation of induced pluripotent stem cells from somatic cells. Methods Mol. Biol. 636, 207-218 (2010).
37. Laurent, L.C. et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 8, 106-118 (2011).
38. Hussein, S.M. et al. Copy number variation and selection during reprogramming to pluripotency. Nature 471, 58-62 (2011).
39. Ohm, J.E. et al. Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells. Cancer Res. 70, 7662-7673 (2010).
40. Harris, W.J. et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 21, 473-487 (2012).
41. Gaudet, F. et al. Induction of tumors in mice by genomic hypomethylation. Science 300, 489-492 (2003).
42. Wollert, K.C. et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 364, 141-148 (2004).
43. Vanneste, E. et al. Chromosome instability is common in human cleavage-stage embryos. Nat. Med. 15, 577-583 (2009).
44. Hyka-Nouspikel, N. et al. Deficient DNA damage response and cell cycle checkpoints lead to accumulation of point mutations in human embryonic stem cells. Stem Cells 30, 1901-1910 (2012).
45. Desmarais, J.A. et al. Human embryonic stem cells fail to activate CHK1 and commit to apoptosis in response to DNA replication stress. Stem Cells 30, 1385-1393 (2012).
46. Mayshar, Y. et al. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 7, 521-531 (2010).
47. Draper, J.S. et al. Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells. Nat. Biotechnol. 22, 53-54 (2004).
48. Lefort, N. et al. Human embryonic stem cells reveal recurrent genomic instability at 20q11.21. Nat. Biotechnol. 26, 1364-1366 (2008).
49. Spits, C. et al. Recurrent chromosomal abnormalities in human embryonic stem cells. Nat. Biotechnol. 26, 1361-1363 (2008).
50. Amps, K. et al. Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat. Biotechnol. 29, 1132-1144 (2011).
51. Werbowetski-Ogilvie, T.E. et al. Characterization of human embryonic stem cells with features of neoplastic progression. Nat. Biotechnol. 27, 91-97 (2009).
52. Newman, A.M. & Cooper, J.B. Lab-specific gene expression signatures in pluripotent stem cells. Cell Stem Cell 7, 258-262 (2010).
53. Narsinh, K.H. et al. Single cell transcriptional profiling reveals heterogeneity of human induced pluripotent stem cells. J. Clin. Invest. 121, 1217-1221 (2011).
54. Pearl, J.I., Kean, L.S., Davis, M.M. & Wu, J.C. Pluripotent stem cells: immune to the immune system? Sci. Transl. Med. 4, 164ps125 (2012).
55. de Almeida, P.E., Ransohoff, J.D., Nahid, A. & Wu, J.C. Immunogenicity of pluripotent stem cells and their derivatives. Circ. Res. 112, 549-561 (2013).
56. Zhao, T., Zhang, Z.N., Rong, Z. & Xu, Y. Immunogenicity of induced pluripotent stem cells. Nature 474, 212-215 (2011).
57. Araki, R. et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 494, 100-104 (2013).
58. Guha, P., Morgan, J.W., Mostoslavsky, G., Rodrigues, N.P. & Boyd, A.S. Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell 12, 407-412 (2013).
59. Drukker, M. et al. Characterization of the expression of MHC proteins in human embryonic stem cells. Proc. Natl. Acad. Sci. USA 99, 9864-9869 (2002).
60. Rideout, W.M. III, Hochedlinger, K., Kyba, M., Daley, G.Q. & Jaenisch, R. Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Cell 109, 17-27 (2002).
61. Pearl, J.I. et al. Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell 8, 309-317 (2011).
62. Swijnenburg, R.J. et al. Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proc. Natl. Acad. Sci. USA 105, 12991-12996 (2008).
63. Schwartz, S.D. et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 379, 713-720 (2012).
64. Choo, A.B. et al. Selection against undifferentiated human embryonic stem cells by a cytotoxic antibody recognizing podocalyxin-like protein-1. Stem Cells 26, 1454-1463 (2008).
65. Tang, C. et al. An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nat. Biotechnol. 29, 829-834 (2011).
66. Dubois, N.C. et al. SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. Nat. Biotechnol. 29, 1011-1018 (2011).
67. Ben-David, U. et al. Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell 12, 167-179 (2013).
68. Peckham, M.J., McElwain, T.J., Barrett, A. & Hendry, W.F. Combined management of malignant teratoma of the testis. Lancet 314, 267-270 (1979).
69. Di Stasi, A. et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673-1683 (2011).
70. Herszfeld, D. et al. CD30 is a survival factor and a biomarker for transformed human pluripotent stem cells. Nat. Biotechnol. 24, 351-357 (2006).